139 related articles for article (PubMed ID: 9769946)
1. [Mdm2, p53 and the cell cycle: when well enough is best left alone].
Maréchal V
Pathol Biol (Paris); 1997 Dec; 45(10):824-32. PubMed ID: 9769946
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
3. The mdm2 proto-oncogene.
Haines DS
Leuk Lymphoma; 1997 Jul; 26(3-4):227-38. PubMed ID: 9322885
[TBL] [Abstract][Full Text] [Related]
4. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.
Dubs-Poterszman MC; Tocque B; Wasylyk B
Oncogene; 1995 Dec; 11(11):2445-9. PubMed ID: 8570197
[TBL] [Abstract][Full Text] [Related]
5. MDM2 oncogene as a novel target for human cancer therapy.
Zhang ; Wang H
Curr Pharm Des; 2000 Mar; 6(4):393-416. PubMed ID: 10788589
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells.
Yang HL; Dong YB; Elliott MJ; Liu TJ; Atienza C; Stilwell A; McMasters KM
Clin Cancer Res; 1999 Aug; 5(8):2242-50. PubMed ID: 10473112
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
Chène P
Nat Rev Cancer; 2003 Feb; 3(2):102-9. PubMed ID: 12563309
[TBL] [Abstract][Full Text] [Related]
8. p53-independent activities of MDM2 and their relevance to cancer therapy.
Zhang Z; Zhang R
Curr Cancer Drug Targets; 2005 Feb; 5(1):9-20. PubMed ID: 15720185
[TBL] [Abstract][Full Text] [Related]
9. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
Mendoza S; Konishi T; Dernell WS; Withrow SJ; Miller CW
Anticancer Res; 1998; 18(6A):4449-53. PubMed ID: 9891508
[TBL] [Abstract][Full Text] [Related]
10. Induction of p53-, MDM2-, and WAF1/CIP1-like molecules in insect cells by DNA-damaging agents.
Bae I; Smith ML; Fornace AJ
Exp Cell Res; 1995 Apr; 217(2):541-5. PubMed ID: 7698255
[TBL] [Abstract][Full Text] [Related]
11. The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target.
Picksley SM; Spicer JF; Barnes DM; Lane DP
Acta Oncol; 1996; 35(4):429-34. PubMed ID: 8695156
[TBL] [Abstract][Full Text] [Related]
12. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the mdm2 oncogene by thyroid hormone receptor.
Qi JS; Yuan Y; Desai-Yajnik V; Samuels HH
Mol Cell Biol; 1999 Jan; 19(1):864-72. PubMed ID: 9858609
[TBL] [Abstract][Full Text] [Related]
14. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.
Chen L; Lu W; Agrawal S; Zhou W; Zhang R; Chen J
Mol Med; 1999 Jan; 5(1):21-34. PubMed ID: 10072445
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
17. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen CY; Oliner JD; Zhan Q; Fornace AJ; Vogelstein B; Kastan MB
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2684-8. PubMed ID: 8146175
[TBL] [Abstract][Full Text] [Related]
18. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of the MDM2 oncogene in leukemia and lymphoma.
Watanabe T; Ichikawa A; Saito H; Hotta T
Leuk Lymphoma; 1996 May; 21(5-6):391-7, color plates XVI following 5. PubMed ID: 9172803
[TBL] [Abstract][Full Text] [Related]
20. Selective compartmentalization of different mdm2 proteins within the nucleus.
Maxwell SA
Anticancer Res; 1994; 14(6B):2541-7. PubMed ID: 7872679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
